Karyopharm Therapeutics Inc. $KPTI Shares Sold by Adage Capital Partners GP L.L.C.

Adage Capital Partners GP L.L.C. decreased its position in shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI - Free Report) by 93.3% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 421,322 shares of the company's stock after selling 5,898,520 shares during the quarter. Adage Capital Partners GP L.L.C. owned 4.92% of Karyopharm Therapeutics worth $1,576,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. T. Rowe Price Investment Management Inc. acquired a new stake in shares of Karyopharm Therapeutics during the first quarter worth about $523,000. Velan Capital Investment Management LP acquired a new stake in shares of Karyopharm Therapeutics during the fourth quarter worth about $27,000. Two Sigma Advisers LP lifted its holdings in shares of Karyopharm Therapeutics by 145.5% during the fourth quarter. Two Sigma Advisers LP now owns 76,600 shares of the company's stock worth $52,000 after purchasing an additional 45,400 shares during the period. Two Sigma Investments LP lifted its holdings in shares of Karyopharm Therapeutics by 60.3% during the fourth quarter. Two Sigma Investments LP now owns 137,786 shares of the company's stock worth $93,000 after purchasing an additional 51,856 shares during the period. Finally, Shay Capital LLC acquired a new stake in shares of Karyopharm Therapeutics during the fourth quarter worth about $116,000. Institutional investors and hedge funds own 66.44% of the company's stock.

Karyopharm Therapeutics Price Performance

KPTI stock traded down $0.19 during trading on Friday, hitting $6.45. 65,890 shares of the company traded hands, compared to its average volume of 182,404. The stock's 50-day simple moving average is $5.24 and its 200 day simple moving average is $5.22. The company has a market cap of $55.92 million, a PE ratio of -0.44 and a beta of 0.35. Karyopharm Therapeutics Inc. has a 1 year low of $3.51 and a 1 year high of $16.95.

Karyopharm Therapeutics (NASDAQ:KPTI - Get Free Report) last announced its quarterly earnings results on Monday, August 11th. The company reported ($4.32) earnings per share for the quarter, missing the consensus estimate of ($3.80) by ($0.52). The company had revenue of $37.93 million during the quarter, compared to the consensus estimate of $37.92 million. Karyopharm Therapeutics has set its FY 2025 guidance at EPS. Research analysts expect that Karyopharm Therapeutics Inc. will post -0.71 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts recently commented on KPTI shares. Robert W. Baird decreased their target price on Karyopharm Therapeutics from $42.00 to $25.00 and set an "outperform" rating for the company in a report on Tuesday, August 12th. HC Wainwright downgraded Karyopharm Therapeutics from a "buy" rating to a "neutral" rating in a report on Wednesday, July 16th. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $34.00.

Karyopharm Therapeutics Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).